The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Abstract
Background No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD. Methods We did a multicentre, double-blind, randomised placebo-controlled phase 2/3 study at 99 outpatient specialty clinics or hospitals in 25 countries. Eligible participants were adults (≥18 years old) with a diagnosis of NMOSD, an Expanded Disability Status Scale score of 8·0 or less, and a history of at least one attack requiring rescue therapy in the year before screening or at least two attacks requiring rescue therapy in the 2 years before screening. Participants were randomly allocated (3:1) to 300 mg intravenous inebilizumab or placebo with a central interactive voice response system or interactive web response system and permuted block randomisation. Inebilizumab or placebo was administered on days 1 and 15. Participants, investigators, and all clinical staff were masked to the treatments, and inebilizumab and placebo were indistinguishable in appearance. The primary endpoint was time to onset of an NMOSD attack, as determined by the adjudication committee. Efficacy endpoints were assessed in all randomly allocated patients who received at least one dose of study intervention, and safety endpoints were assessed in the as-treated population. The study is registered with ClinicalTrials.gov, number NCT02200770. Findings Between Jan 6, 2015, and Sept 24, 2018, 230 participants were randomly assigned to treatment and dosed, with 174 participants receiving inebilizumab and 56 receiving placebo. The randomised controlled period was stopped before complete enrolment, as recommended by the independent data-monitoring committee, because of a clear demonstration of efficacy. 21 (12%) of 174 participants receiving inebilizumab had an attack versus 22 (39%) of 56 participants receiving placebo (hazard ratio 0·272 [95% CI 0·150-0·496]; p<0·0001). Adverse events occurred in 125 (72%) of 174 participants receiving inebilizumab and 41 (73%) of 56 participants receiving placebo. Serious adverse events occurred in eight (5%) of 174 participants receiving inebilizumab and five (9%) of 56 participants receiving placebo. Interpretation Compared with placebo, inebilizumab reduced the risk of an NMOSD attack. Inebilizumab has potential application as an evidence-based treatment for patients with NMOSD. Funding MedImmune and Viela Bio.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In any case, the long-term persistence of (re-)activatable autoantigen-specific ThEx cells in patients in remission may well explain the less-than-perfect treatment efficacy of steroid-sparing agents, 64-67 depletion of CD19/CD20 memory B cells, 68,69 as well as exacerbation of disease by b -IFN. 27,70”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [68]
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
Self-citationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationEculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J. A., Nakashima, I., Terzi, M., Totolyan, N. A., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 887
Self-citationAn open label study of the effects of rituximab in neuromyelitis optica
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. L., & Genain, C. P. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Self-citationNeuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Self-citationIntrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica
Bennett, J. L., Lam, C., Kalluri, S. R., Saikali, P., Bautista, K., Dupree, C., Glogowska, M. J., Case, D., Antel, J. P., Owens, G. P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21802 · Cited by 593
Self-citationNeuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 585
Self-citationSaadoun, S., Waters, P., Bell, B., Vincent, A., Verkman, A., & Papadopoulos, M. (2010) · Brain : a journal of neurology · doi:10.1093/brain/awp309 · Cited by 574
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Damato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H. ‐. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400118 · Cited by 287
B lymphocytes in neuromyelitis optica
Bennett, J. L., O’Connor, K. C., Bar‐Or, A., Zamvil, S. S., Hemmer, B., Tedder, T. F., von Büdingen, H. ‐., Stüve, O., Yeaman, M. R., Smith, T. J., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000104 · Cited by 186
Self-citationFrequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis
Jarius, S., Frederiksen, J. L., Waters, P. J., Paul, F., Akman‐Demir, G., Marignier, R., Franciotta, D. M., Ruprecht, K., Kuenz, B., Rommer, P. S., et al. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.07.011 · Cited by 168
Self-citationAgius, M. A., Kłodowska-Duda, G. A., Maciejowski, M., Potemkowski, A., Li, J., Patra, K., Wesley, J. B., Madani, S., Barron, G., Katz, E., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517740641 · Cited by 150
Self-citationChen, D., Gallagher, S., Monson, N. L., Herbst, R., & Wang, Y. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5120107 · Cited by 110
Fujihara, K., Misu, T., Nakashima, I., Takahashi, T., Bradl, M., Lassmann, H., Takano, R., Nishiyama, S., Takai, Y., Suzuki, C., et al. (2012) · Clinical and Experimental Neuroimmunology · doi:10.1111/j.1759-1961.2012.00030.x · Cited by 93
Self-citationSchiopu, E., Chatterjee, S., Hsu, V. M., Flor, A., Cimbora, D. M., Patra, K., Yao, W., Li, J., Streicher, K. L., McKeever, K., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1021-2 · Cited by 81
Self-citationPlacebo-controlled study in neuromyelitis optica—Ethical and design considerations
Cree, B., Bennett, J. L., Sheehan, M., Cohen, J. A., Hartung, H.-P., Aktaş, O., Kim, H. J., Paul, F., Pittock, S. J., Weinshenker, B. G., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515620934 · Cited by 76
Self-citationDisease exacerbation after rituximab induction in neuromyelitis optica
Perumal, J. S., Kister, I., Howard, J., & Herbert, J. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000061 · Cited by 69
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders
Ciron, J., Audoin, B., Bourre, B., Brassat, D., Durand‐Dubief, F., Laplaud, D. A., Maillart, É., Papeix, C., Vukusic, S., Zéphir, H., et al. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2017.11.005 · Cited by 61
Self-citationInvestigational drugs in development to prevent neuromyelitis optica relapses
Paul, F., Murphy, O. C., Pardo, S., & Levy, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1443077 · Cited by 46
Self-citationPlacebo controlled trials in neuromyelitis optica are needed and ethical
Cree, B. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.07.017 · Cited by 10
Self-citationStatistical Considerations for an Adaptive Design for a Serious Rare Disease
Patra, K., Cree, B., Katz, E., Pulkstenis, E. P., Dmitrienko, A. A., & Cutter, G. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015619203 · Cited by 5
Self-citation
Cited by
Sorted by citations
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 684
Myelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo‐Calvo, Á., Pröbstel, A., Aktaş, O., Alexopoulos, H., Amato, M. P., Asgari, N., Banwell, B., Bennett, J. L., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 545
Self-citationTraboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30078-8 · Cited by 513
Self-citationJarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 503
Self-citationKaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 431
“Inebilizumab demonstrated a favorable safety and tolerability profile, with an adverse event rate similar to placebo.(47)”
Background
Metadata
- Authors
- Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., Green, A. J., Aktas, O., Hartung, H.-P., Lublin, F. D., Drappa, J., Barron, G., Madani, S., Ratchford, J. N., She, D., Cimbora, D., & Katz, E.
- Affiliations
- University of California, San Francisco (US)
- University of Colorado Anschutz (US)
- National Cancer Center (KR)
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Fukushima Medical University (JP)
- Max Delbrück Center (DE)
- University of Alabama at Birmingham (US)
- Hospices Civils de Lyon (FR)
- Heinrich Heine University Düsseldorf (DE)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Cree, Bruce A C
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 394
- Issue
- 10206
- Pages
- 1352-1363
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2972221943
- Cited by
- 756
- References
- 26
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 102 · 2023: 101 · 2022: 102 · 2021: 117 · 2020: 101 · 2019: 7
- FWCI
- 58.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Hospices Civils de Lyon
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neuromyelitis optica spectrum disorder, inebilizumab, anti-CD19, B-cell depletion, relapse prevention, disability progression, Expanded Disability Status Scale, treatment-emergent adverse events, autoimmune CNS disease, treatment efficacy and safety, relapse-free survival
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Neuromyelitis Optica, Prospective Studies, Severity of Illness Index, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
